200 related articles for article (PubMed ID: 20509970)
1. Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives.
Tseng CY; Mane JY; Winter P; Johnson L; Huzil T; Izbicka E; Luduena RF; Tuszynski JA
Mol Cancer; 2010 May; 9():131. PubMed ID: 20509970
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.
Kumbhar BV; Borogaon A; Panda D; Kunwar A
PLoS One; 2016; 11(5):e0156048. PubMed ID: 27227832
[TBL] [Abstract][Full Text] [Related]
3. Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids.
Santoshi S; Naik PK
J Comput Aided Mol Des; 2014 Jul; 28(7):751-63. PubMed ID: 24916062
[TBL] [Abstract][Full Text] [Related]
4. Computational design and biological testing of highly cytotoxic colchicine ring A modifications.
Torin Huzil J; Winter P; Johnson L; Weis AL; Bakos T; Banerjee A; Luduena RF; Damaraju S; Tuszynski JA
Chem Biol Drug Des; 2010 Jun; 75(6):541-50. PubMed ID: 20408852
[TBL] [Abstract][Full Text] [Related]
5. Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes.
Kumbhar BV; Panda D; Kunwar A
PLoS One; 2018; 13(3):e0194934. PubMed ID: 29584771
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel 5-(4-chlorophenyl)furan derivatives with inhibitory activity on tubulin polymerization.
Moussa SA; A Osman EE; Eid NM; Abou-Seri SM; El Moghazy SM
Future Med Chem; 2018 Aug; 10(16):1907-1924. PubMed ID: 29966433
[TBL] [Abstract][Full Text] [Related]
8. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV; Panda D; Kunwar A
J Biomol Struct Dyn; 2020 Feb; 38(2):426-438. PubMed ID: 30831055
[TBL] [Abstract][Full Text] [Related]
9. Novel Colchicine Derivatives and their Anti-cancer Activity.
Johnson L; Goping IS; Rieger A; Mane JY; Huzil T; Banerjee A; Luduena R; Hassani B; Winter P; Tuszynski JA
Curr Top Med Chem; 2017; 17(22):2538-2558. PubMed ID: 28056740
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes.
Majcher U; Urbaniak A; Maj E; Moshari M; Delgado M; Wietrzyk J; Bartl F; Chambers TC; Tuszynski JA; Huczyński A
Bioorg Chem; 2018 Dec; 81():553-566. PubMed ID: 30248507
[TBL] [Abstract][Full Text] [Related]
11. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
12. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines.
Morishita J; Nurse P
Open Biol; 2021 Sep; 11(9):210161. PubMed ID: 34493069
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation and molecular docking studies of new amides of 4-chlorothiocolchicine as anticancer agents.
Klejborowska G; Urbaniak A; Maj E; Preto J; Moshari M; Wietrzyk J; Tuszynski JA; Chambers TC; Huczyński A
Bioorg Chem; 2020 Apr; 97():103664. PubMed ID: 32106039
[TBL] [Abstract][Full Text] [Related]
15. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
16. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
Lobert S; Frankfurter A; Correia JJ
Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities.
Li G; Wang Y; Li L; Ren Y; Deng X; Liu J; Wang W; Luo M; Liu S; Chen J
Eur J Med Chem; 2020 Sep; 202():112519. PubMed ID: 32650183
[TBL] [Abstract][Full Text] [Related]
18. Electrostatic contributions to colchicine binding within tubulin isotypes.
Huzil JT; Barakat K; Tuszynski JA
Electromagn Biol Med; 2009; 28(4):355-64. PubMed ID: 20017626
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic substituted indolizines as new colchicine site tubulin polymerisation inhibitors.
Sardaru MC; Craciun AM; Al Matarneh CM; Sandu IA; Amarandi RM; Popovici L; Ciobanu CI; Peptanariu D; Pinteala M; Mangalagiu II; Danac R
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1581-1595. PubMed ID: 32752898
[TBL] [Abstract][Full Text] [Related]
20. Identification of Essential 2D and 3D Chemical Features for Discovery of the Novel Tubulin Polymerization Inhibitors.
Azimi F; Ghasemi JB; Saghaei L; Hassanzadeh F; Mahdavi M; Sadeghi-Aliabadi H; Scotti MT; Scotti L
Curr Top Med Chem; 2019; 19(13):1092-1120. PubMed ID: 31109275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
